No Data
No Data
君聖泰醫藥-B:2023年報
Changes in Hong Kong stocks | Junshengtai Pharmaceutical-B (02511) once rose more than 42% and previously announced the completion of the phase IIb clinical trial of HTD1801 to enroll patients
Junshengtai Pharmaceutical-B (02511) once rose by more than 42%. As of press release, it rose 23.49% to HK$5.31, with a turnover of HK$12.3888 million.
Hong Kong stock changes丨Junshengtai Pharmaceutical-B surged more than 44%, and the stock price hit a new high in about three weeks
Gelonghui, April 15 | Junshengtai Pharmaceutical-B (2511.HK) bucked the trend in the afternoon. At one point, it surged more than 44% to HK$6.2, recovering lost ground since April. The stock price hit a new high of about three weeks since March 26, with a market value of about HK$3.2 billion. In early April, Junshengtai Pharmaceutical announced that the Phase IIb clinical trial of the enterohepatic anti-inflammatory and metabolic regulator HTD1801 (Xiongdeoxycholic Berberibe) independently developed by the company has completed patient enrollment. The trial targets patients with type 2 diabetes (T2DM) or metabolic fatty hepatosis with prediabetes. According to reports, Jun Shengtai was founded in 2011 to specialize in
HighTide Therapeutics Completes Patient Enrolment for Phase II Trial of Metabolic Modulator
HighTide Therapeutics (HKG:2511) has completed patient enrollment for the Phase II-b clinical trial of HTD1801, a gut-liver anti-inflammatory metabolic modulator, a Wednesday filing on the Hong Kong b
Junshengtai Pharmaceutical-B (02511.HK): HTD1801 clinical trial to treat metabolic steatohepatitis (MASH) phase IIb completed patient enrollment
Gelonghui, April 3 | Junshengtai Pharmaceutical-B (02511.HK) announced that the Phase IIb clinical trial of the enterohepatic anti-inflammatory and metabolic regulator HTD1801 (Xiongdeoxycholic Berberberis), developed independently by the company, has enrolled patients. The trial targets patients with metabolic fatty hepatosis (MASH for short) with type 2 diabetes (T2DM) or pre-diabetes. This trial (Centricity study) is a randomized, double-blind, placebo-controlled global multicenter phase IIb clinical trial aimed at evaluating HTD1801 in
Junshengtai Pharmaceutical-B (02511) released annual results, R&D costs of 312 million yuan, an increase of 70.6% over the previous year
Junshengtai Pharmaceutical-B (02511) announced 2023 results, other revenue and revenue of 34.2 million yuan (people...
No Data